battery

Barrel Energy Signs MOU With American Lithium…

LAS VEGAS, March 04, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to announce it has signed a Memorandum of Understanding to enter a partnership with American Lithium Minerals, Inc (“AMLM”) (OTC:AMLM) for production facilities in North America.

As previously announced, on February 10th 2021, Barrel signed an exclusive agreement with Roshan Energy Technologies www.roshantechnologies.in/ (“Roshan”) that will allow for Barrel to become the majority stakeholder in Roshan and the expansion of its Lithium battery facilities in India. Roshan has developed an impressive line of Lithium Battery products for Electric Vehicles, Medical Equipment, Solar street lighting, the telecom industry as well as home energy storage solutions. Barrel and Roshan first plan to make a sizeable impact on the escalating small vehicle EV market in India, a country that has made ambitious policies towards the change to EVs. Roshan has already signed contracts to supply an assortment of manufacturers of two and three wheeled EVs.

Additionally, the Barrel-Rosha agreement allows for Barrel to establish a U.S. based manufacturing unit for key Roshan battery products and designs. The Barrel and AMLM MOU is designed to allow Barrel to have its first base for entry into U.S. based manufacturing and use new selective recycling technologies developed by Roshan team that offer both crucial waste-management and battery metal supply solutions.

The non-exclusive AMLM agreement calls for Lithium products to be pilot tested, manufactured and even recycled at one or more its industrial complexes. The technology, operations and products will be provided by Barrel through its agreement with Roshan Energy, as well as any technology sourced by AMLM.

The proposed first location by AMLM is within the heartland of U.S. manufacturing with nearby high population density, sufficient power, square footage and accessibility by rail, road, and water.

About American Lithium Minerals (OTC Markets AMLM) is engaged in mineral exploration for lithium and rare earth minerals (REE) in the southwest U.S and are active in Lithium Complexes, intended to process high-grade lithium ore, assemble lithium-ion batteries and recycle spent lithium-ion batteries.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America.

www.BarrelEnergyandTech.com

Contact: Louis Silver, Investor Relations
1-610-710-1303
info@BarrelEnergyandTech.com

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Source link

CBD

CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dys…

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This application has been initiated via the 505(b)(2) drug approval pathway, and is in continuation of FDA-provided feedback in support of CURE’s clinical development plans for its CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED).

CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience.

“We are so excited to advance our oral soluble film sildenafil citrate program to human clinical trials as we continue to focus our resources on a few key areas of differentiation – including applying our film technology to therapies for critical central nervous system (CNS) disease states as well as antiviral therapeutics,” said Vered Gigi, Chief Scientific Officer.

“This is an important milestone in our overall clinical program,” said Robert Davidson, CEO of CURE. “CUREfilm Blue is our first pharmaceutical product that utilizes our patented drug delivery platform to enter the human clinical phase. We believe delivering the main active ingredient sildenafil through this technology could improve the overall patient experience of those struggling with ED and become the new standard for treatment of the indication. We are using an expedited regulatory pathway through the FDA that we hope will enable us to bring this product to market faster than most other clinical program candidates.”

The global erectile dysfunction drug market is projected to reach approximately USD$6.6 Billion by 2025, at a CAGR of 6.0% over the five-year forecasted period with sildenafil representing a majority of the market according to a report by QYR Research.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

1 Viagra® is a registered trademark of Pfizer Inc.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005441/en/

Contacts

Licensing Contact:
Jonathan Berlent
Chief Business Officer
CURE Pharmaceutical
Jberlent@curepharma.com
516.660.9148

Investment Contact:
Gary Zwetchkenbaum
Plum Tree Consulting LLC
gzplumtree@gmail.com
516.455.7662

Media Contact:
Kathryn Brown
CMW Media
cure@cmwmedia.com
858.264.6600


Source link

battery

Barrel Energy Announces Entry into Share Purchase…

LAS VEGAS, Feb. 22, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to announce pleased to announce the execution of a Share Purchase Agreement (“SPA”) with Flote App Inc. (“Flote”), the designers of advance social media, virtual reality and cryptocoin platforms.

In consideration for the share purchase agreement, Barrel’s per share purchase price is based upon specific pre-market valuations of Flote and the Company will be entitled to acquire an aggregate of 45% equity into the cutting-edge company by way of two tiered tranches.

Flote are the creators of a massive new Social Network system built on respect for each user’s personal data, privacy and pocketbook. The all-encompassing Flote platform fully delivers on the internet’s promise of a wholly connected community without big tech censorship, murky guidelines, and infringement. On Flote, people can regain their privacy, express themselves freely, build communities, chat, text and earn digital money by engagement or providing valuable content. The powerful platform provides a valuable marketspace with multi-currency wallets and more ways for content providers and creators to monetize their goods and services, even including their content from third-party social applications like Facebook or Twitter.

Barrel’s first tranche of Common shares, equal to a 25% interest in the equity of Flote, is based upon a $10,000,000.00 (Ten Million Dollars) valuation; and the second tranche of Common shares of the Company, equal to a further 20% interest, is based upon a $30,000,000.00 (Thirty Million Dollars) valuation for Flote. Barrel has already executed and delivered the first portion of the initial 25% tranche.

As Flote ramps up its marketing and development it will move some operations into the Barrel Technology Center. Flote has also developed a cryptocurrency token based on the Ethereum blockchain which will be integral part of the entire Flote social ecosystem, fully able to support fast and autonomous business or personal monetary transactions.

Flote’s advanced factory of developers are also currently working on gaming systems with integrated online wallets within a Virtual Reality environment. Flote has now launched the website www.FloteFactory.com and can be followed on Twitter @floteofficial.

Barrel and Flote are currently planning real world applications for a digital coin that will be integral to the expanding green energy sector. The use of ‘Green Coin’ could serve as a boom to Lithium explorers, producers, exporters and importers that could rely on upon a powerful digital currency of trade that replaces the world of the Petro-dollar. Decentralized finance with digital tokens offers optimal flexibility and global use. The Barrel and Flote team up is committed to create a new ecosystem that would benefit green energy assets with a smart contract led liquidity pool that could bypass conventional finance instruments and the inflationary fluctuations of fiat currencies.

Barrel and Flote anticipate Flotes’ full public launch will be completed within Q2 of 2021 with shares trading on the U.S., Canada and Frankfurt exchange. Additionally, Barrel plans to adapt and dedicate its large hemp-acreage in California as a replacement battery recycling area from Nevada as there are potential farming by products from the technology and it is closer to a population of 9 million people.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America.

Contact: Louis Silver, Investor Relations
1-610-710-1303
info@BarrelEnergyandTech.com

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Source link

battery

Barrel Energy Appoints Stuart Hensman to Board of Directors

LAS VEGAS, Feb. 16, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to announce the appointment of Mr. Stuart Philip Hensman to the Board of Directors effective immediately.

Mr. Hensman possesses both a Bachelor of Arts and Master of Science degree and has held a number of executive leadership roles setting investment strategy and corporate policies worldwide. He has occupied the position of Chairman & Chief Executive Officer for Scotia Capital Inc. (USA), as Managing Director (Equities) for Scotia Capital Inc (United Kingdom), Chairman of the Board of Governors at CI Funds, Chairman of Board of Creststreet Asset Management and Chairman of the Board of Creststreet Power and Income Fund.

In addition to chairing the above noted Boards, Mr. Hensman, has also chaired Audit, Compensation and Governance and Nominating Committees on number of other Boards where he served.

Craig Alford, CEO of Barrel Energy states, “We’re extremely pleased to welcome Mr. Hensman to the Barrel Energy. Mr. Hensman brings to our board a wealth of knowledge in global business, strategy development and regulatory oversight. We look forward to benefitting from his valuable counsel as we continue to grow Barrel.”

Mr. Hensman joins the Company at an exciting time of rapid expansion into a number of verticals within the critical aspects of the materials and tech for Electric Vehicles, battery performance, renewables and integrated devices. Collective technologies that will underpin this decades multi-billion-dollar market expansion toward zero carbon solutions.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America and abroad.

Contact:
Harp Sangha/Chairman
+17025952247
harp@barrelenergyandtech.com

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Source link

CBD

CURE Pharmaceutical Announces Promotions and Additions to Board of Directors

CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors.

After his dedicated tenure as Chairman of the Board, Mr. William Yuan is transitioning to Chairman Emeritus and will continue to serve the Company as a Key Advisor. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. and currently serves on the board of US Retina of Denver, CO. Past board service consists of Lead Director of Athenahealth; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL. Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee and he was COO and Deputy Administrator of the Centers for Medicare and Medicaid Services (CMS) during the administration of President George W. Bush, administering a federal budget of $600 billion. Mr. King-Shaw also served as Senior Advisor to the Secretary of the US Treasury.

He is currently serving as Chief Strategy Officer of Steward Health Care Systems, LLC, and has held C-suite positions with leading private companies including Neighborhood Health Partnership, Inc. and JMH Health Plan.

Additionally, the Company welcomes Dov Szapiro to its Board. Mr. Szapiro brings more than 20 years of experience as a CEO, investor, advisor, and board member in companies across multiple industries and different growth phases. Currently, he serves as a Co-Founder, Managing Partner and Principal of Entourage Effect Capital, one of the cannabis industry’s most highly regarded investment firms. Prior to Entourage Effect Capital, Mr. Szapiro co-founded AFS Acceptance LLC, where he served as President and CEO. As AFS’ CEO, Mr. Szapiro’s main responsibility was to provide the vision and strategic leadership for AFS to expand into 30 states. In 2015, Mr. Szapiro led the negotiations of a strategic sale to Credito Real SAB de CV, Mexico’s largest non-bank financial institution listed in the Mexican Stock Exchange. Prior to co-founding AFS, Mr. Szapiro was a Director of business development for GovWorks, Inc, an internet start-up in the e-government sector. Earlier in his career, Mr. Szapiro was an analyst for Bassini, Playfair + Associates, a $1.2 billion emerging markets private equity firm. Mr. Szapiro also serves as Member of the Board of Directors of several companies including Conception Nurseries, a global leader focused on tissue culture micropropagation for the cannabis industry.

“We thank Mr. Yuan for his dedicated leadership of CURE’s Board of Directors and we are honored to have him stay with us as Chairman Emeritus and Key Advisor to the Board and executive team, as he leads the Company in its continued progress for dynamic international expansion and global revenue traction. As our Company continues to grow and evolve, so does our Board of Directors and we are confident in Mr. King-Shaw Jr.’s ability to lead our Board in continued success,” said CURE Pharmaceutical Chief Executive Officer Rob Davidson. “We are also honored to have Mr. Szapiro join us as one of the cannabis industry’s lead investors. Through his decades of experience as a founder and CEO leading companies from scaling up to exit, as well as an investor and board member, he has gained valuable knowledge of what it takes to drive a publicly traded company to success and we look forward to working with him in our various business development initiatives, driving an accretive M&A strategy to execute our growth plans and further expand our presence in the wellness space, including the endocannabinoid research division.”

To learn more about CURE, visit https://www.curepharmaceutical.com/.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005337/en/

Contacts

Investment Media Contact:
Kathryn Brown
Account Supervisor
CMW Media
cure@cmwmedia.com
858-264-6600

Investor Relations:
Gary Zwetchkenbaum
Plum Tree Consulting
(516) 455-7662
gzplumtree@gmail.com


Source link

battery

Barrel Energy Signs MOU for Lithium Battery Production in India and North Americ…

LAS VEGAS, Feb. 10, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to announce it has signed a Memorandum of Understanding to enter a partnership with Roshan Energy Technologies Pvt. Ltd (“Roshan”), located in Hyderabad, India, for Lithium Battery development and production in India and North America.

As part of the venture, Barrel will become a majority stakeholder in Roshan allowing Barrel Energy the platform for expansion into the massive India market and into international markets. Roshan and Barrel plan on establishing a U.S. based manufacturing unit for key battery designs within Roshan’s line of Lithium products.

A joint R&D division will be developed in conjunction with Barrels’ Nevada Tech Center as part of the partnership. Roshan’s Ashok Shukla, a professor emeritus with 40 years’ research experience of specialized batteries and over 350 published technical papers will lead the team with the aim of designing customized solutions for battery development, improvement, and recycling.

As part of this transformative deal, Roshan and Barrel will first establish a Lithium Battery Manufacturing facility in India. Plans for the facility with a three phase roll out of powerful products has been in development by Roshan’s CEO and engineering team leader, Mr. S.A. Gaffoor. Mr. Gaffoor, a veteran electrical Engineer and entrepreneur, has over 25 years in designing and developing industrial battery products and holds 10 patents for advanced battery technologies.

India is a nation on the forefront of innovation and technology and represents one of the largest markets for Electric Vehicles (EVs) worldwide with plans to become an all EV nation by 2030. Roshan has already developed strong partnerships in China with deals with Guangzhou Great Power Energy & Technology Co (http://www.greatpower.net) and Suzhou Chilwee New Energy Power Technology Co. (http://www.sz-cpet.com/en/) and has a impressive line of Lithium Battery products for EVs, Medical Equipment, Solar street lighting, the telecom industry as well as medium and large energy storage.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America.

Contact:
Harp Sangha/Chairman
+17025952247/sanghaharp1964@gmail.com

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Source link

CBD

Sera Labs Unveils ImmunD₃ an Important New Offering to the Nutri-Strips Produc…

Sera Labs Pioneers the Delivery of Next Generation Immune Support in the Continued Battle Against the COVID-19 Pandemic

According to the National Institute of Health (NIH) more than 50 percent of people worldwide have Vitamin D insufficiency. In response, Sera Labs, Inc., a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today that it is unveiling “ImmunD₃,” a convenient, science-backed oral thin-film that provides a weekly dose of Vitamin D (40,000 IU) as a part of its Nutri-Strips™ line of novel and innovative vitamins and supplements. Sera Labs has also launched an easy-to-navigate, e-commerce website at Seralabshealth.com and Nutristrips.com to further facilitate consumer awareness and to provide availability of this beneficial health promoting product. Sera Labs continues its initiatives to introduce other innovative product offerings for both the health and wellness, beauty, and pets categories.

All Nutri-Strips™ products are expertly-designed using the RAD₃ (Rapid Activation Delivery) oral thin film strip technology offering targeted supplement dosing that activates directly on the tongue, eliminating the need for water, chewing or struggling to swallow pills.

“While Americans are becoming more wellness-focused, the ability to dedicate the necessary time is becoming less and less each year. Sera Labs’ once weekly 40,000 IU’s of Vitamin D leverages the science of rapid delivery for on-the-go and instant activation,” said Nancy Duitch, Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer. “The innovation of Nutri-Strips oral thin-film is a game changer in the nutraceutical sector and we believe that ImmunD₃ and our other Nutri-Strips™ products are leading the evolution of the dietary supplement industry with a focus on getting people the supplements they need in a fast, easy, and efficient way. In addition to our new e-commerce website, we are also launching a national TV advertising campaign in order to reach consumers, helping boost our robust omnichannel marketing strategy and to increase awareness for the brand.”

Vitamin D plays an important and well-established role in keeping the body’s immune system running efficiently. A recent study suggests a strong correlation between COVID-19 and Vitamin D deficiency as 82.2 percent of COVID-19 patients studied were also deficient in Vitamin D.

Visit www.seralabshealth.com to learn more about “ImmunD₃™” and other high-quality products.

About SeraLabs

Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: www.Seralabshealth.com and follow us on Instagram at @theseralabs, Twitter, or on Facebook or contact: press@theseralabs.com

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

https://www.ncbi.nlm.nih.gov/books/NBK532266/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405052/

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005340/en/

Contacts

Monica M. Jaramillo, LABEL the Agency, mjaramillo@labeltheagency.com, 424.273.8675
Investor and Corporate Relations, Kathryn Brown, cure@cmwmedia.com, 858.264.6600




Source link

battery

Barrel Energy to Open Technology Center in Nevada

LAS VEGAS, Feb. 08, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to announce the opening of the company’s research and technology center in Las Vegas, NV. The facility will strengthen Barrels’ green-energy product development and various collaborative technology efforts.

Barrel recognizes the current deficiencies, as well as the massive potential, in the Lithium-ion battery supply chain as market and environmental forces propel the coming dominance of Zero-Emission vehicles with companies like Tesla, GM, Ford, Apple and others drive this vital technology. Despite their current market share, Electric Vehicles (EVs) are currently the fastest growing segment of the auto industry.

The new center will be the locus for Barrel’s efforts into Lithium-Ion Battery metal recycling as well as potential battery development and direct metal ion extraction. Barrel intends to immerse itself into the key materials and technology that will underpin this decades coming surge in EV dominance.

Additionally, a section of the center will be dedicated to developmental support and on-site innovative I.P. efforts as Barrel finalizes its discussions with a number of next-level software and related technology partnerships.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America.

Contact:
Louis Silver, Director of Corporate Communications
lsilver35@verizon.net
+1-610-710-1303

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Source link

CBD

Sera Labs, Inc. Wins Prestigious Retail Excellence Award

Health, Wellness, CBD and plant-based anti-aging skincare powerhouse, Sera Labs wins Drug Store News’ annual Natural Products Award

The retailers have spoken! Sera Labs, Inc., the wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR), announced today they have won the coveted Retail Excellence (REX Award) for Natural Products.

The Rex Awards have a long history of recognizing, and honoring category leaders in the industry. Sera Labs, the premiere health, wellness and anti-aging CBD and plant-based skincare company beat out hundreds of nominees for this highly sought-after recognition.

Retailers confidentially nominate businesses who are trailblazing and shaking up the industry with cutting-edge technology, as well as marketing and distribution which directly drive sales into the retailer. “Our team is comprised of seasoned marketers who always have the retailer top of mind,” said Nancy Duitch, Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer. “Receiving this award by the retailers and Drug Store News is a benchmark of success for the company and special honor for our team.”

Sera Labs’ mission is to be a solution-based company for their customers and retailers. The company uses only the highest quality ingredients and most stringent of testing for potency and accuracy. Additionally, in Q2 the company will launch new product innovations and a category creator hero product which will change the beauty industry.

Winners of this award are companies who have helped shape the natural category and led the way in product innovation and merchandising. “We are proud to recognize Sera Labs as a 2021 recipient of the Drug Store News Retail Excellence Awards — Natural,” said Seth Mendelson, Editor in Chief and Associate Publisher of Drug Store News magazine. “Retailers constantly tell us the importance of having new brands and products on their shelves. The REX awards show what companies are taking those steps to bring innovation to the merchant and to help drive sales and profits. Sera Labs is one of those companies that stand on the cutting edge.”

“My confidence in the Sera Labs team has never been stronger and it is an honor to work alongside such dedicated and talented professionals,” said Rob Davidson, CURE Pharmaceutical CEO. “This award is one of many that Sera Labs has already received and I look forward to witnessing the many recognitions to come.”

Sera Labs can be found online and in national and regional store chains. For more information visit: www.Seralabshealth.com and follow us on Facebook, Twitter, or Instagram @theseralabs, or contact: press@theseralabs.com.

About SeraLabs

Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: www.Seralabshealth.com and follow us on Instagram at @theseralabs, Twitter, or on Facebook or contact: press@theseralabs.com

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005448/en/

Contacts

Media Contacts:
Monica M. Jaramillo, LABEL the Agency, mjaramillo@labeltheagency.com, 424.273.8675
Investor and Corporate Relations, Kathryn Brown, cure@cmwmedia.com, 858.264.6600




Source link

battery

Barrel Energy to Provide Tech Space for Lithium Battery Recycling

LAS VEGAS, Jan. 28, 2021 (GLOBE NEWSWIRE) — Barrel Energy Inc. (the “Company” or “Barrel”) (OTC: BRLL) is pleased to provide an update on the company’s recent activities.

The CEO of Barrel Energy Mr. Craig Alford is, at this time, also assisting Altair International Corp. (ATAO: OTC) to develop ATAO’s prized lithium/rare earth and gold assets in Nevada. Mr. Alford was also the founder of American Battery Metals Corp. The Chairman of Barrel Energy, Mr. Harp Sangha and Mr. Alford are also the founders of Lithium Now.

Barrel Energy is aware that most analysts see an upcoming bull market for Lithium and other battery raw materials to feed the surging Lithium-ion battery supply chain and has made this is a strategic focus for the company.

Global demand for these key battery materials is expected to rise dramatically over this decade. The outlook for Lithium will outstrip production with global demand for Lithium expected to increase 650% by 2027. Market demand for Lithium has been predicted to be a staggering 470,000mt by 2025. Each 1% increase in new global Electric Vehicles sales could further increase Lithium demand by 70,000mt, nearly representing the total of last year’s annual production of Lithium.

Barrel has recently been in discussions with St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF) (FSE: 85G1) (“St-Georges”) a Canadian public company engaged in the development of new Lithium extraction technologies regarding several sites for their Lithium processing technology centers within the southwest U.S.

Barrel is considering location sites with a specific eye toward cost efficiency and process permitting. Access to infrastructure, sufficient power, transport and nearby source material and demand are all factors for project viability. Our lead development site is situated on a roughly 30 acre property that is now zoned for industrial activities located in Nevada just 18.5 miles from the Tesla Gigafactory 1.

About Barrel: Barrel Energy Inc., (OTC Markets: BRLL) is focused on several ventures within the energy and minerals sector and the rapid development of valuable production opportunities throughout North America.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission.

Contact:
Harp Sangha,
Chairman
7025952247
Harp@barrelenergyinc.com

Source link